FLUTICASONE FUROATE TEVA 27.5 micrograms/pulvérisation, suspension for spraying nasal bottle, 10.4 g
Active ingredients: Fluticasone furoate
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for sprayingbottle, 10.4 gnasale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FLUTICASONE FUROATE TEVA 27,5 microgrammes/pulvérisation, suspension pour pulvérisation nasale
- Pharmaceutical form
- suspension pour pulvérisation
- Route of administration
- nasale
- Presentation description
- 1 flacon en verre brun de 10,4 g (correspondant à 120 pulvérisations) de suspension avec pompe doseuse et pulvérisateur nasal
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Jan 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66160831CIP73029332CIP133400930293324Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUROATE DE FLUTICASONEsuspension | 27,5 microgrammes · une pulvérisation délivrée | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.